

SUPPLEMENTAL FILE FOR: A comparative medical genomics approach may facilitate the interpretation of rare missense variation

TABLE OF CONTENTS

Supplemental Table 1.....2

Supplemental Table 2.....15

Supplemental Figure 1.....28

Supplemental Figure 2.....29

Supplemental Figure 3.....30

Supplemental Figure 4.....31

Supplemental Figure 5.....32

Supplemental References.....33

Supplemental Table 1. Non-human animal missense variants (n=339) extracted from OMIA and studied in humans. See text for details.

Gene Symbol	Chr	Genomic Position (hg19)	Ref Allele	Alt Allele	Classification of Orthologous Human Variant in ClinVar	gnomAD Allele Frequency (v2.1.1) ¹		phyloP Score ²	REVEL Score ³	AlphaMissense Score ⁴
						Genome seq	Exome seq			
<i>ABCA1</i>	9	107646745	C	T	ABSENT	0	0	0.935	0.911	0.9782
<i>ABCA12</i>	2	215815679	A	G	ABSENT	0	0	1.199	0.949	0.9935
<i>ACSL5</i>	10	114168275	C	G	ABSENT	0	0	0.927	0.195	0.1602
<i>ACVR1</i>	2	158630626	C	T	LP/P	0	0	0.935	0.948	0.9581
<i>ADAMTS10</i>	19	8654389	C	T	ABSENT	0	4E-06	0.852	0.859	0.9977
<i>ADAMTS10</i>	19	8661222	C	T	ABSENT	0	0	0.935	0.785	0.9425
<i>ADAMTS17</i>	15	100673442	C	T	ABSENT	0	0	0.847	0.732	0.9738
<i>ADAMTS2</i>	5	178552032	C	T	VUS	0	1.2E-05	0.852	0.275	0.1486
<i>ADAMTSL2</i>	9	136406102	C	T	LP/P	0	0	0.852	0.467	0.5975
<i>ADAMTSL4</i>	1	150530585	G	A	ABSENT	0	7.6E-05	0.154	0.033	0.0752
<i>AGTPBP1</i>	9	88201870	C	G	ABSENT	0	0	0.935	0.688	0.999
<i>AGXT</i>	2	241810860	G	A	LP/P	0	0	0.887	0.945	0.975
<i>AGXT</i>	2	241808659	G	A	ABSENT	0	0	0.898	0.837	0.275
<i>ALDH5A1</i>	6	24523122	G	A	ABSENT	0	0	1.045	0.888	0.9058
<i>ALMS1</i>	2	73777489	G	C	ABSENT	0	0	1.048	0.368	NA
<i>ALPL</i>	1	21903126	T	G	ABSENT	0	0	1.058	0.8	0.1902
<i>AR</i>	X	66931514	G	C	ABSENT	0	0	1.047	0.955	0.9995
<i>AR</i>	X	66937392	C	T	ABSENT	0	0	0.85	0.912	0.9575
<i>ARSB</i>	5	78181645	C	T	VUS	3.2E-05	8E-06	0.935	0.984	0.9611
<i>ARSB</i>	5	78076401	A	G	ABSENT	0	0	1.088	0.977	0.9935
<i>ARSB</i>	5	78076270	C	T	ABSENT	0	0	0.852	0.633	0.3668

Haque, Guirguis, et al.

3

ARSG	17	66339822	G	A	VUS	0	2.4E-05	1.048	0.621	0.6041
ASIP	20	32856947	T	A	ABSENT	0	0	0.9	0.636	0.8136
ASIP	20	32856863	C	T	ABSENT	0	0	0.795	0.183	0.3526
ASPA	17	3402296	G	C	ABSENT	0	0	0.998	0.926	0.9502
ASPRV1	2	70187847	A	G	ABSENT	0	0	1.088	0.173	0.9158
ATF2	2	175986219	A	C	ABSENT	0	0	1.136	0.695	0.9988
ATG4D	19	10663609	G	A	ABSENT	0	0	0.065	0.037	0.0944
ATP13A2	1	17323577	G	A	ABSENT	0	0	1.048	0.871	0.9491
ATP2A1	16	28909686	C	T	ABSENT	0	3.2E-05	0.848	0.935	0.9987
ATP2A1	16	28898747	G	T	ABSENT	0	0	0.953	0.964	0.9902
ATP2A1	16	28898972	G	T	ABSENT	0	0	0.902	0.858	0.8338
ATP7A	X	77245098	C	T	ABSENT	0	0	0.852	0.594	0.1894
BCKDHA	19	41930425	C	T	ABSENT	0	0	0.935	0.56	0.4864
BEST1	11	61724316	G	A	ABSENT	0	0	1.048	0.985	0.9659
BMP15	X	50659434	A	C	ABSENT	0	5.5E-06	0.211	0.612	0.2127
BMP15	X	50659387	G	A	ABSENT	0	0	0.953	0.97	0.9852
BMP15	X	50659525	G	T	ABSENT	0	0	0.127	0.711	0.929
BMP15	X	50659375	C	T	ABSENT	0	0	0.044	0.303	0.1591
BMP3	4	81974618	C	A	ABSENT	0	0	0.935	0.815	0.993
BMPR1B	4	96051173	A	G	ABSENT	0	4E-06	1.199	0.704	0.7864
BRAF	7	140453136	A	T	LP/P	0	4E-06	1.193	0.931	0.9927
CAD	2	27447710	A	G	VUS	3.2E-05	2.8E-05	1.199	0.949	0.7597
CAPN1	11	64950951	G	A	ABSENT	0	0	1.048	0.881	0.9997
CAT	11	34478287	G	A	ABSENT	0	0	1.048	0.673	0.1547
CD320	19	8368785	G	C	ABSENT	0	4.3E-06	-0.309	0.88	0.9404
CDH23	10	73330622	C	T	ABSENT	0	0	0.934	0.846	NA
CHAT	10	50827789	G	A	CIP	0.0002	0.00004	0.953	0.804	0.5351
CHST6	16	75512976	G	T	ABSENT	0	0	0.813	0.779	0.2157

Haque, Guirguis, et al.

4

<i>CLCN1</i>	7	143016944	G	A	ABSENT	0	4E-06	1.048	0.342	0.0716
<i>CLCN1</i>	7	143021535	C	G	ABSENT	0	0	0.935	0.892	0.8213
<i>CLCN1</i>	7	143039214	A	C	ABSENT	0	0	1.187	0.666	0.4716
<i>CLCN1</i>	7	143048744	G	C	ABSENT	0	0	0.953	0.628	0.8425
<i>CLN6</i>	15	68510888	G	A	CIP	0	8E-06	1.048	0.926	0.9585
<i>CLN6</i>	15	68500588	A	G	ABSENT	0	0	1.088	0.863	0.9949
<i>CNGA3</i>	2	99012861	C	T	LP/P	0	4E-05	0.935	0.846	0.3505
<i>CNGA3</i>	X	150912464	G	A	ABSENT	0	0	1.045	0.972	0.9862
<i>CNGB3</i>	8	87679206	C	T	ABSENT	0	1.2E-05	0.935	0.796	0.6972
<i>CNGB3</i>	8	87679206	C	T	ABSENT	0	1.2E-05	0.935	0.796	0.6972
<i>CNTNAP1</i>	17	40845375	G	A	ABSENT	0	8E-06	1.048	0.821	0.9682
<i>COL10A1</i>	6	116441496	C	T	ABSENT	0	0	0.935	0.925	0.8733
<i>COL11A2</i>	6	33157186	C	G	ABSENT	0	0	-0.001	0.095	0.5283
<i>COL1A1</i>	17	48273017	C	T	ABSENT	0	0	0.935	0.976	0.7926
<i>COL1A1</i>	17	48272838	C	G	ABSENT	0	0	0.935	0.961	0.807
<i>COL1A1</i>	17	48263763	A	T	ABSENT	0	0	1.028	0.662	0.618
<i>COL2A1</i>	12	48376666	C	T	ABSENT	0	0	0.935	0.991	0.9204
<i>COL2A1</i>	12	48372397	C	T	ABSENT	0	0	0.935	0.995	0.9777
<i>COL2A1</i>	12	48378812	C	T	ABSENT	0	0	0.935	0.993	0.9994
<i>COL2A1</i>	12	48371210	C	T	ABSENT	0	0	0.852	0.993	0.9423
<i>COL2A1</i>	12	48372091	C	T	ABSENT	0	0	0.935	0.942	0.8857
<i>COL5A1</i>	9	137707826	G	A	VUS	0	0	0.943	0.969	0.9945
<i>COL5A2</i>	2	189921724	C	A	ABSENT	0	0	0.892	0.947	0.9838
<i>COL6A3</i>	2	238274501	G	A	VUS	0.0002	4E-05	0.953	0.131	0.108
<i>COL7A1</i>	3	48613963	C	T	ABSENT	0	0	0.892	0.771	0.1912
<i>COLQ</i>	3	15498031	A	G	LP/P	0	0	1.199	0.845	0.8338
<i>COLQ</i>	3	15497411	C	T	ABSENT	0	0	0.87	0.894	0.9472
<i>COLQ</i>	3	15499767	C	T	ABSENT	0	0	0.935	0.285	0.1033

<i>COPA</i>	1	160302256	G	A	ABSENT	0	0	1.048	0.704	0.9882
<i>CORIN</i>	4	47625754	G	A	ABSENT	0	2.4E-05	0.998	0.268	0.1958
<i>CORIN</i>	4	47695070	C	T	ABSENT	0	0	0.888	0.974	0.9822
<i>CPTIC</i>	19	50200599	G	A	ABSENT	0	0	1.036	0.734	0.5224
<i>CSNK1G2</i>	19	1978903	G	C	ABSENT	0	0	0.859	0.932	1
<i>CTSD</i>	11	1775313	C	T	ABSENT	0	0	0.852	0.856	0.9981
<i>CTSD</i>	11	1778655	C	T	ABSENT	0	0	0.881	0.376	0.9648
<i>CYB5R3</i>	22	43027384	C	T	ABSENT	3.2E-05	1.3E-05	0.852	0.908	0.891
<i>CYB5R3</i>	22	43023363	T	G	ABSENT	0	0	0.076	0.441	0.2783
<i>CYP26C1</i>	10	94822610	T	C	ABSENT	0	0	0.828	0.901	0.927
<i>DKK4</i>	8	42233272	C	T	ABSENT	0	0	0.826	0.661	0.9281
<i>DKK4</i>	8	42234511	G	A	ABSENT	0	0	1.048	0.038	0.339
<i>DMD</i>	X	32360270	G	A	CIP	0	2.8E-05	1.048	0.212	0.1353
<i>DNMI</i>	9	130982538	G	T	ABSENT	0	0	1.048	0.715	0.9167
<i>DNM2</i>	19	10909219	C	T	LP/P	0	0	-0.035	0.83	0.9079
<i>DPYS</i>	8	105405152	C	T	LP/P	0	8E-06	0.935	0.872	0.9731
<i>DSP</i>	6	7584358	C	A	ABSENT	0	0	0.935	0.72	0.9988
<i>DUOX2</i>	15	45401730	T	C	ABSENT	0	0	1.011	0.764	0.8356
<i>EDN2</i>	1	41949787	C	T	ABSENT	0	0	0.852	0.928	0.984
<i>EDNRA</i>	4	148461045	G	A	ABSENT	0	8E-06	0.953	0.536	0.6778
<i>EDNRA</i>	4	148453825	G	T	ABSENT	0	0	1.048	0.795	0.9977
<i>ENAM</i>	4	71507856	C	T	ABSENT	0	0	0.935	0.166	0.1776
<i>ENTREP2</i>	15	29428645	T	C	ABSENT	0	1.3E-05	0.913	0.18	0.085
<i>ETFDH</i>	4	159616656	T	G	ABSENT	0	0	0.964	0.925	0.9203
<i>F11</i>	4	187207634	G	A	VUS	0	2.8E-05	1.048	0.903	0.4246
<i>F12</i>	5	176829582	C	G	ABSENT	0	0	0.785	0.782	0.5487
<i>F8</i>	X	154189400	G	C	ABSENT	0	0	1.048	0.991	0.9594
<i>F8</i>	X	154091390	A	T	ABSENT	0	0	1.199	0.936	0.9645

<i>F8</i>	X	154185266	C	T	ABSENT	0	0	0.852	0.925	0.9961
<i>F9</i>	X	138644124	G	A	ABSENT	0	0	1.048	0.993	0.9893
<i>FAM20C</i>	7	295908	C	T	ABSENT	0	7.1E-06	0.883	0.754	0.8671
<i>FAM83G</i>	17	18907200	C	G	ABSENT	0	0	-0.012	0.21	0.7512
<i>FBN1</i>	15	48777685	C	T	ABSENT	0	0	0.935	0.933	0.9807
<i>FGF5</i>	4	81207591	C	T	ABSENT	0	4E-06	0.935	0.893	0.9937
<i>FGF5</i>	4	81188256	G	T	ABSENT	0	0	1.048	0.907	0.998
<i>FGF5</i>	4	81207590	G	A	ABSENT	0	0	1.048	0.875	0.9793
<i>FGF5</i>	4	81207488	A	C	ABSENT	0	0	1.199	0.044	0.8405
<i>FGFR2</i>	10	123279562	C	A	LP/P	0	0	0.892	0.982	0.9999
<i>FGFR3</i>	4	1808341	T	A	ABSENT	0	0	1.049	0.802	0.988
<i>FLCN</i>	17	17125830	T	C	ABSENT	0	0	1.061	0.957	0.9979
<i>FZD7</i>	2	202900611	G	C	ABSENT	0	4E-06	1.048	0.791	0.9477
<i>G6PC1</i>	17	41059562	G	C	ABSENT	0	0	0.953	0.899	0.9664
<i>GALC</i>	14	88450799	T	G	ABSENT	0	0	1.011	0.931	0.8029
<i>GART</i>	21	34900853	T	G	ABSENT	0	0	0.964	0.65	0.8083
<i>GDF9</i>	5	132197700	G	A	LP/P	0	8E-06	0.712	0.484	0.1934
<i>GDF9</i>	5	132197364	T	G	ABSENT	0	0	1.061	0.875	0.9922
<i>GDF9</i>	5	132197459	G	A	ABSENT	0	0	1.048	0.85	0.8223
<i>GDF9</i>	5	132197532	C	T	ABSENT	0	0	0.935	0.5	0.468
<i>GDF9</i>	5	132197609	A	C	ABSENT	0	0	1.199	0.393	0.6187
<i>GDF9</i>	5	132199997	G	A	ABSENT	0	0	1.04	0.192	0.1105
<i>GFAP</i>	17	42990701	C	T	LP/P	0	0	0.935	0.902	0.5695
<i>GLB1</i>	3	33114105	C	T	LP/P	0	3.6E-05	0.892	0.941	0.5309
<i>GLB1</i>	3	33058235	C	G	ABSENT	0	0	0.932	0.942	0.9874
<i>GLB1</i>	3	33099625	C	A	ABSENT	0	0	0.807	0.901	0.8685
<i>GUSB</i>	7	65441045	G	A	CIP	0	8E-06	0.912	0.945	0.9131
<i>GUSB</i>	7	65435316	G	A	ABSENT	0	2E-05	1.048	0.934	0.8431

Haque, Guirguis, et al.

7

<i>GUSB</i>	7	65439917	C	T	ABSENT	0	0	0.847	0.95	0.9274
<i>GUSB</i>	7	65435319	A	C	ABSENT	0	0	0.158	0.282	0.1253
<i>HCRTR2</i>	6	55039545	G	A	ABSENT	0	0	0.953	0.448	0.9166
<i>HES7</i>	17	8027398	A	G	ABSENT	0	0	1.199	0.346	0.4372
<i>HEXA</i>	15	72637818	G	A	LP/P	0	4E-06	1.048	0.888	0.9397
<i>HEXA</i>	15	72641439	C	T	ABSENT	0	0	0.935	0.964	0.9063
<i>HMBS</i>	11	118959966	G	A	ABSENT	0	0	1.048	0.837	0.6996
<i>IARS1</i>	9	95050449	C	G	ABSENT	0	0	0.935	0.474	0.9716
<i>IFT122</i>	3	129234353	G	A	ABSENT	0	1.6E-05	0.94	0.663	0.7181
<i>ITGA2B</i>	17	42460879	C	G	ABSENT	0	0	-0.774	0.586	0.7564
<i>ITGA3</i>	17	48148681	C	T	ABSENT	0	4E-06	0.935	0.407	0.2516
<i>ITGB2</i>	21	46323396	T	C	ABSENT	0	0	0.964	0.982	0.9936
<i>ITGB2</i>	21	46330239	C	G	ABSENT	0	0	0.935	0.939	0.9935
<i>KCNG1</i>	20	49620870	C	A	ABSENT	0	0	0.932	0.952	0.9963
<i>KCNJ10</i>	1	160011337	A	G	ABSENT	0	0	1.199	0.663	0.8078
<i>KDM2B</i>	12	121880815	C	T	ABSENT	0	0	0.935	0.053	0.3299
<i>KDSR</i>	18	61018135	C	T	ABSENT	0	0	0.935	0.31	0.1947
<i>KIF1C</i>	17	4905937	G	A	ABSENT	0	8E-06	1.048	0.916	0.9635
<i>KIF3B</i>	20	30898580	G	A	ABSENT	0	0	1.048	0.868	0.9116
<i>KIT</i>	4	55575645	A	G	VUS	0	1.2E-05	1.199	0.359	0.0986
<i>KIT</i>	4	55604682	G	A	VUS	0	2E-05	1.048	0.108	0.0642
<i>KIT</i>	4	55595543	T	C	ABSENT	0	0	1.061	0.976	0.9999
<i>KIT</i>	4	55595543	T	A	ABSENT	0	0	1.061	0.971	0.9995
<i>KIT</i>	4	55599304	T	A	ABSENT	0	0	0.113	0.927	1
<i>KIT</i>	4	55598160	A	T	ABSENT	0	0	1.14	0.898	0.926
<i>KIT</i>	4	55595523	A	T	ABSENT	0	0	0.238	0.872	0.9886
<i>KIT</i>	4	55594269	G	A	ABSENT	0	0	1.048	0.847	0.9997
<i>KIT</i>	4	55565844	T	C	ABSENT	0	0	1.061	0.761	0.9745

Haque, Guirguis, et al.

8

<i>KIT</i>	4	55594031	C	T	ABSENT	0	0	0.935	0.679	0.9983
<i>KIT</i>	4	55569989	G	A	ABSENT	0	0	1.048	0.451	0.7469
<i>KIT</i>	4	55589840	A	G	ABSENT	0	0	1.199	0.329	0.4299
<i>KLKB1</i>	4	187172760	T	A	ABSENT	0	0	0.963	0.753	0.6779
<i>KRT25</i>	17	38911258	C	T	ABSENT	0	4E-06	0.935	0.937	0.3718
<i>KRT27</i>	17	38938470	G	C	ABSENT	0	0	-0.64	0.774	0.9798
<i>KRT5</i>	12	52910431	C	T	LP/P	0	0	0.935	0.895	0.9786
<i>KRT71</i>	12	52944024	G	A	ABSENT	0	2.8E-05	1.048	0.769	0.6363
<i>L2HGDH</i>	14	50713867	T	C	ABSENT	0	0	1.061	0.904	0.9751
<i>LAMA3</i>	18	21512141	A	T	ABSENT	0	0	1.199	0.604	0.973
<i>LAMB3</i>	1	209801494	A	G	ABSENT	0	0	1.194	0.956	0.9723
<i>LAMP3</i>	3	182841997	C	T	ABSENT	0	0	0.789	0.418	0.3219
<i>LDLR</i>	19	11215925	C	T	LP/P	0	2.8E-05	0.888	0.81	0.4117
<i>LOXHD1</i>	18	44085947	C	G	ABSENT	0	0	0.935	0.859	0.9255
<i>LRP4</i>	11	46897459	C	T	ABSENT	0	0	0.919	0.953	0.674
<i>LRP4</i>	11	46903348	C	T	ABSENT	0	0	0.919	0.95	0.9967
<i>LVRN</i>	5	115298993	G	A	ABSENT	0	0	0.949	0.194	0.1824
<i>LYST</i>	1	235929441	T	C	ABSENT	0	0	1.011	0.851	0.966
<i>MAN2B1</i>	19	12772142	A	G	ABSENT	0	0	1.088	0.881	0.9961
<i>MAN2B1</i>	19	12774621	C	T	ABSENT	0	0	0.935	0.811	0.7674
<i>MARS2</i>	2	198571682	G	A	ABSENT	0	0	0.953	0.445	0.5059
<i>MC1R</i>	16	89985962	T	C	VUS	0	4E-06	0.964	0.207	0.315
<i>MC1R</i>	16	89985962	T	C	VUS	0	4E-06	0.964	0.207	0.315
<i>MC1R</i>	16	89985916	G	A	LB/B	3.2E-05	4E-06	0.953	0.601	0.2372
<i>MC1R</i>	16	89985916	G	A	ABSENT	3.2E-05	4E-06	0.953	0.601	0.2372
<i>MC1R</i>	16	89986384	G	A	ABSENT	3.2E-05	3.6E-05	0.039	0.514	0.0924
<i>MC1R</i>	16	89986148	C	T	ABSENT	3.2E-05	3.7E-05	0.852	0.085	0.1252
<i>MC1R</i>	16	89986090	C	T	ABSENT	6.4E-05	2.9E-05	0.014	0.857	0.1787

Haque, Guirguis, et al.

9

<i>MC1R</i>	16	89985940	G	A	ABSENT	0.0763	0.0781	-0.333	0.039	0.1201
<i>MC1R</i>	16	89986070	T	A	ABSENT	0	0	0.964	0.898	0.3537
<i>MC1R</i>	16	89986316	A	C	ABSENT	0	0	1.028	0.702	0.2547
<i>MC1R</i>	16	89986467	C	G	ABSENT	0	0	0.069	0.594	0.6414
<i>MC1R</i>	16	89985929	G	A	ABSENT	0	0	0.953	0.349	0.6499
<i>MC1R</i>	16	89986027	G	A	ABSENT	0	0	0.953	0.317	0.2437
<i>MC1R</i>	16	89986027	G	A	ABSENT	0	0	0.953	0.317	0.2437
<i>MC1R</i>	16	89985884	T	A	ABSENT	0	0	0.089	0.289	0.2335
<i>MC1R</i>	16	89985946	G	A	ABSENT	0	0	0.953	0.275	0.3161
<i>MC1R</i>	16	89985884	T	C	ABSENT	0	0	0.089	0.139	0.0876
<i>MC4R</i>	18	58038691	C	T	ABSENT	6.4E-05	8E-06	0.935	0.371	0.9448
<i>MITF</i>	3	70008453	T	C	VUS	0	0	1.061	0.963	1
<i>MITF</i>	3	70001032	A	G	CIP	0	0	1.199	0.824	0.9979
<i>MITF</i>	3	70008444	G	A	LP/P	0	0	1.048	0.882	1
<i>MITF</i>	3	70005618	G	T	ABSENT	0	0	1.048	0.966	1
<i>MLPH</i>	2	238402172	C	T	LP/P	3.2E-05	2.4E-05	-2.117	0.623	0.5533
<i>MLPH</i>	2	238428672	G	C	ABSENT	0	0	1.034	0.13	0.2153
<i>MOCOS</i>	18	33767639	T	C	ABSENT	0	0	0.935	0.446	0.7402
<i>MRC2</i>	17	60754698	T	G	ABSENT	0	0	0.954	0.739	0.9821
<i>MSTN</i>	2	190922174	C	T	ABSENT	0	0	0.807	0.974	0.9998
<i>MSTN</i>	2	190927132	A	G	ABSENT	0	0	1.199	0.889	0.9993
<i>MSTN</i>	2	190924991	C	T	ABSENT	0	0	0.935	0.181	0.0885
<i>MSTN</i>	2	190927009	G	C	ABSENT	0	0	1.048	0.171	0.1811
<i>MTBP</i>	8	121534921	G	A	ABSENT	0	0	1.044	0.378	0.1765
<i>MTMI</i>	X	149826391	A	C	ABSENT	0	0	1.14	0.95	0.9863
<i>MTMI</i>	X	149807426	C	T	ABSENT	0	0	0.935	0.893	0.8038
<i>MXI</i>	21	42830462	G	A	ABSENT	0	0	-0.317	0.122	0.1559
<i>MYBPC1</i>	12	102036319	T	G	LP/P	0	0	1.061	0.823	0.5828

Haque, Guirguis, et al.

10

MYBPC3	11	47359086	G	A	CIP	0	4E-06	0.076	0.65	0.8113
MYBPC3	11	47372991	C	G	ABSENT	0	0	0.892	0.489	0.9726
MYH1	17	10416047	T	C	ABSENT	0	0	1.061	0.777	0.5552
MYH7	14	23883224	C	T	VUS	3.2E-05	0	0.932	0.879	0.7712
MYO7A	11	76901153	G	A	LP/P	0	7.5E-05	0.988	0.951	0.9982
NAGLU	17	40695378	G	A	LP/P	0	1.2E-05	0.092	0.653	0.6898
NAPEPLD	7	102760427	C	G	ABSENT	0	0	0.892	0.842	0.994
NDRG1	8	134274323	C	A	ABSENT	0	0	0.935	0.792	0.9983
NECAP1	12	8245519	G	A	ABSENT	0	0	1.036	0.237	0.4966
NHLRC2	10	115644032	T	C	ABSENT	0	0	1.006	0.877	0.6448
NPC1	18	21118578	G	C	ABSENT	0	0	1.048	0.954	0.9103
NPC1	18	21119363	C	G	ABSENT	0	0	0.935	0.728	0.9946
NPC1	18	21136211	T	G	ABSENT	0	0	1.061	0.664	0.6993
NSDHL	X	152036164	G	A	ABSENT	0	0	1.048	0.941	0.9867
NSDHL	X	152031158	A	G	ABSENT	0	0	1.199	0.89	0.8701
NUBPL	14	32142695	C	A	ABSENT	0	0	0.935	0.663	0.9915
P3H2	3	189688652	C	G	ABSENT	0	0	0.927	0.07	0.1412
PAX3	2	223161809	C	T	ABSENT	0	0	0.935	0.982	0.9999
PAX3	2	223161923	G	C	ABSENT	0	0	1.048	0.675	0.9683
PCDH15	10	55780104	G	C	ABSENT	0	0	1.048	0.152	0.1347
PFAS	17	8172081	C	T	ABSENT	0	2E-05	0.925	0.454	0.3573
PFKM	12	48527220	C	T	ABSENT	9.6E-05	3.2E-05	0.02	0.842	0.9917
PIGN	18	59824406	G	A	ABSENT	0	0	1.048	0.583	0.646
PITX3	10	103990842	C	G	ABSENT	3.2E-05	0	0.769	0.934	0.9998
PKD1	16	2150031	C	T	ABSENT	0	0	0.846	0.255	0.9036
PKLR	1	155264148	C	T	LP/P	9.6E-05	5.6E-05	0.932	0.959	0.568
PKLR	1	155264390	A	G	ABSENT	0	0	1.136	0.812	0.6757
PLN	6	118880110	G	A	CIP	3.2E-05	8E-06	0.953	0.906	0.1589

<i>PLOD1</i>	1	12034713	G	A	CIP	0	2.8E-05	1.045	0.893	0.989
<i>PLP1</i>	X	103040616	A	C	ABSENT	0	0	1.199	0.936	0.9787
<i>PLP2</i>	X	49028397	C	T	ABSENT	0	0	0.764	0.125	0.2719
<i>PMEL</i>	12	56359732	C	T	ABSENT	0	0	0.031	0.036	0.1947
<i>PNKP</i>	19	50370313	T	C	ABSENT	0	0	1.061	0.33	0.8662
<i>PNPLA8</i>	7	108128384	C	T	ABSENT	0	0	0.892	0.688	0.9964
<i>PPARD</i>	6	35378959	G	A	ABSENT	0	0	0.953	0.457	0.076
<i>PPIB</i>	15	64455071	C	T	ABSENT	0	0	0.865	0.433	0.9798
<i>PRCD</i>	17	74536228	G	A	LP/P	0	0	1.048	0.825	0.8828
<i>PRKAG3</i>	2	219693283	C	T	VUS	0	1.6E-05	0.935	0.9	0.8395
<i>PRL</i>	6	22287660	A	C	ABSENT	0	0	1.199	0.976	0.959
<i>PRNP</i>	20	4680464	G	A	LP/P	0	4E-06	0.953	0.761	0.7744
<i>PRNP</i>	20	4680245	G	A	LP/P	0	4E-06	0.953	0.812	0.5322
<i>PRNP</i>	20	4680318	G	A	ABSENT	6.4E-05	2.8E-05	0.953	0.625	0.2165
<i>PRNP</i>	20	4680318	G	A	ABSENT	6.4E-05	2.8E-05	0.953	0.625	0.2165
<i>PRNP</i>	20	4680264	C	T	ABSENT	0	0	0.852	0.717	0.1883
<i>PRNP</i>	20	4680285	A	G	ABSENT	0	0	1.088	0.659	0.1437
<i>PRNP</i>	20	4680283	A	G	ABSENT	0	0	-1.629	0.341	0.0863
<i>PSMB7</i>	9	127177131	A	C	ABSENT	0	0	1.199	0.562	0.849
<i>PYGM</i>	11	64520595	G	A	ABSENT	0	8E-06	1.048	0.892	0.9789
<i>RAB24</i>	5	176730177	T	G	ABSENT	0	0	0.831	0.755	0.7662
<i>RABGGTB</i>	1	76257870	A	G	ABSENT	0	4E-06	1.199	0.777	0.9368
<i>RASGRP2</i>	11	64506944	A	G	ABSENT	0	0	1.088	0.737	0.9993
<i>RDH5</i>	12	56115704	G	T	ABSENT	0	0	1.048	0.77	0.7757
<i>RETREG1</i>	5	16479075	G	A	ABSENT	0	0	1.048	0.734	0.7485
<i>RHO</i>	3	129247587	C	G	ABSENT	0	0	0.892	0.754	0.436
<i>RYR1</i>	19	38948185	C	T	LP/P	0.0003	8.7E-05	0.852	0.927	0.9627
<i>RYR1</i>	19	38991282	C	G	ABSENT	0	0	0.796	0.893	0.9797

Haque, Guirguis, et al.

12

<i>RYR1</i>	19	38946154	T	C	ABSENT	0	0	0.945	0.757	0.9841
<i>SCN8A</i>	12	52200168	G	T	ABSENT	0	0	1.048	0.893	0.9569
<i>SEL1L</i>	14	81950643	A	G	ABSENT	0	0	1.199	0.531	0.9982
<i>SERPINH1</i>	11	75282848	T	C	ABSENT	0	0	1.061	0.949	0.9809
<i>SGSH</i>	17	78188504	G	A	CIP	3.2E-05	8E-06	0.951	0.942	0.4445
<i>SLC12A1</i>	15	48527101	C	T	ABSENT	0	0	0.892	0.973	0.9063
<i>SLC24A5</i>	15	48414204	T	A	ABSENT	0	0	1.061	0.734	0.4384
<i>SLC25A12</i>	2	172669974	A	G	ABSENT	0	0	1.022	0.939	0.9999
<i>SLC25A46</i>	5	110079477	C	T	ABSENT	0	0	0.935	0.773	0.9609
<i>SLC2A9</i>	4	9982268	C	A	ABSENT	0	0	0.841	0.826	0.9382
<i>SLC35A3</i>	1	100459183	C	A	ABSENT	0	4E-06	0.935	0.624	0.9961
<i>SLC35A3</i>	1	100476990	G	T	ABSENT	0	0	0.998	0.741	0.9849
<i>SLC36A1</i>	5	150843158	C	G	ABSENT	0	0	0.935	0.556	0.9524
<i>SLC39A4</i>	8	145639765	C	G	ABSENT	0	0	0.877	0.505	NA
<i>SLC3A1</i>	2	44539746	C	T	LP/P	3.2E-05	8.4E-05	-0.017	0.943	0.6546
<i>SLC45A2</i>	5	33963887	T	C	ABSENT	0	4E-06	1.061	0.035	0.0778
<i>SLC45A2</i>	5	33944868	C	T	ABSENT	0	8E-06	0.935	0.742	0.7432
<i>SLC45A2</i>	5	33984384	C	T	ABSENT	0	2E-05	0.798	0.917	0.8041
<i>SLC45A2</i>	5	33982446	C	T	ABSENT	0	0	0.927	0.834	0.9482
<i>SLC45A2</i>	5	33954510	C	T	ABSENT	0	0	0.935	0.795	0.7387
<i>SLC45A2</i>	5	33954504	G	T	ABSENT	0	0	1.048	0.161	0.4745
<i>SLC5A3</i>	21	35468849	C	T	ABSENT	0	4E-06	0.935	0.877	0.9716
<i>SLC6A5</i>	11	20628679	T	C	ABSENT	0	0	1.061	0.872	0.9984
<i>SLC7A9</i>	19	33333132	G	A	LP/P	3.2E-05	1.6E-05	1.048	0.871	0.5122
<i>SLC7A9</i>	19	33349368	C	T	ABSENT	0	0	0.935	0.917	0.993
<i>SLC7A9</i>	19	33350748	A	T	ABSENT	0	0	1.199	0.942	0.8032
<i>SLC7A9</i>	19	33353031	C	T	ABSENT	0	0	0.935	0.536	0.837
<i>SMC2</i>	9	106900433	T	C	ABSENT	0	0	1.061	0.768	0.9916

<i>SOD1</i>	21	33036151	G	A	ABSENT	0	0	1.045	0.449	0.1248
<i>SOWAHB</i>	4	77817829	G	T	ABSENT	0	0	0.953	0.096	0.1298
<i>SPAST</i>	2	32370074	G	A	LP/P	0	0	0.953	0.889	0.9887
<i>STAT5B</i>	17	40359728	T	G	ABSENT	0	0	1.061	0.758	0.9917
<i>SUGT1</i>	13	53261902	T	C	ABSENT	0	0	1.061	0.833	0.9998
<i>SUV39H2</i>	10	14941660	T	G	ABSENT	0	0	-0.219	0.876	0.9995
<i>TBXT</i>	6	166580884	T	C	ABSENT	0	0	1.011	0.953	0.9999
<i>TBXT</i>	6	166580891	G	C	ABSENT	0	0	0.12	0.852	0.997
<i>TECPR2</i>	14	102963981	C	T	VUS	3.2E-05	5.1E-05	0.067	0.608	0.9679
<i>TNXB</i>	6	32053766	C	T	ABSENT	0	0	0.935	0.139	0.2902
<i>TPO</i>	2	1491745	C	T	ABSENT	0	1.2E-05	0.807	0.906	0.8571
<i>TPO</i>	2	1440068	G	A	ABSENT	0	0	0.902	0.504	0.4515
<i>TRPV4</i>	12	110236547	C	A	LP/P	0	0	0.935	0.442	0.8876
<i>TSEN54</i>	17	73513639	G	A	ABSENT	0	0	1.048	0.909	0.9089
<i>TUBB1</i>	20	57594582	G	A	ABSENT	0	8E-06	1.048	0.637	0.8966
<i>TUBB1</i>	20	57599227	G	A	ABSENT	0	0	1.048	0.739	0.8421
<i>TUBD1</i>	17	57955604	T	C	ABSENT	0	0	0.955	0.667	0.1455
<i>TUBGCP5</i>	15	22840245	C	A	ABSENT	0	0	NA	0.283	0.3493
<i>TYR</i>	11	88911351	G	A	LP/P	0.0001	8.4E-05	1.048	0.877	0.6493
<i>TYR</i>	11	88961072	C	A	LP/P	0.0004	0.0003	0.852	0.708	0.7055
<i>TYR</i>	11	88924454	G	A	ABSENT	0	0	1.048	0.851	0.4958
<i>TYRPI</i>	9	12695772	C	A	ABSENT	0	4E-06	0.892	0.925	0.9884
<i>TYRPI</i>	9	12698611	G	T	ABSENT	0	1.2E-05	1.048	0.721	0.9872
<i>TYRPI</i>	9	12702382	T	G	ABSENT	0	0	1.009	0.984	0.9639
<i>TYRPI</i>	9	12694117	T	A	ABSENT	0	0	1.061	0.96	0.9824
<i>TYRPI</i>	9	12708035	C	T	ABSENT	0	0	0.892	0.947	0.9104
<i>TYRPI</i>	9	12694121	G	A	ABSENT	0	0	1.048	0.943	0.9489
<i>UCHL1</i>	4	41270049	G	A	ABSENT	0	0	1.048	0.486	0.9341

Haque, Guirguis, et al.

14

<i>UNC93B1</i>	11	67759230	G	T	ABSENT	0	0	NA	NA	NA
<i>UROD</i>	1	45479381	T	C	ABSENT	0	0	1.061	0.969	0.8853
<i>UROS</i>	10	127496045	C	T	ABSENT	0	0	0.935	0.786	0.208
<i>UROS</i>	10	127504753	G	A	ABSENT	0	0	1.048	0.29	0.1585
<i>VPS11</i>	11	118951867	A	G	ABSENT	0	0	1.199	NA	NA
<i>VWF</i>	12	6167087	A	C	ABSENT	0	0	1.053	0.649	0.8761
<i>VWF</i>	12	6127647	T	C	ABSENT	0	0	0.083	0.079	0.0809
<i>WIF1</i>	12	65460443	G	C	ABSENT	0	4E-06	1.048	0.186	0.9735
<i>WWP1</i>	8	87440033	G	A	ABSENT	3.2E-05	0	1.048	0.498	0.883
<i>YARS2</i>	12	32903702	C	T	ABSENT	0	0	0.931	0.501	0.834

Supplemental Table 2. Human genes (n=220) orthologous to the genes with non-human animal missense variants extracted from OMIA and included in this study. See Supplemental Table 1 for details. An asterisk next to a gene symbol indicates that the gene is included in the HRT Atlas v1.0 database list of human housekeeping genes.⁵ OMIM, Online Mendelian Inheritance in Man (<https://www.omim.org/>, accessed 2023).

Gene symbol	OMIM phenotype
<i>ABCA1</i>	HDL deficiency, type 2;Tangier disease, Autosomal recessive
<i>ABCA12</i>	Ichthyosis, congenital, autosomal recessive 4A, Autosomal recessive;Ichthyosis, congenital, autosomal recessive 4B (harlequin), Autosomal recessive
<i>ACSL5</i>	No Mendelian disease association in OMIM
<i>ACVR1</i>	Fibrodysplasia ossificans progressiva, Autosomal dominant
<i>ADAMTS10</i>	Weill-Marchesani syndrome 1, recessive, Autosomal recessive
<i>ADAMTS17</i>	Weill-Marchesani-like syndrome, Autosomal recessive
<i>ADAMTS2</i>	Ehlers-Danlos syndrome, type VIIC, Autosomal recessive
<i>ADAMTSL2</i>	Geleophysic dysplasia 1, Autosomal recessive
<i>ADAMTSL4</i>	Ectopia lentis et pupillae, Autosomal recessive;Ectopia lentis, isolated, autosomal recessive, Autosomal recessive
<i>AGTPBP1</i>	No Mendelian disease association in OMIM
<i>AGXT</i>	Hyperoxaluria, primary, type 1, Autosomal recessive
<i>ALDH5A1</i>	Succinic semialdehyde dehydrogenase deficiency, Autosomal recessive
<i>ALMS1</i>	Alstrom syndrome, Autosomal recessive
<i>ALPL</i>	Hypophosphatasia, adult, Autosomal recessive, Autosomal dominant;Hypophosphatasia, childhood, Autosomal recessive;Hypophosphatasia, infantile, Autosomal recessive;Odontohypophosphatasia, Autosomal recessive, Autosomal dominant
<i>AR</i>	Androgen insensitivity, X-linked recessive;Androgen insensitivity, partial, with or without breast cancer, X-linked recessive;Hypospadias 1, X-linked, X-linked recessive;Spinal and bulbar muscular atrophy of Kennedy, X-linked recessive

<i>ARSB</i>	Mucopolysaccharidosis type VI (Maroteaux-Lamy), Autosomal recessive
<i>ARSG</i>	Usher syndrome, type IV
<i>ASIP</i>	No Mendelian disease association in OMIM
<i>ASPA</i>	Canavan disease, Autosomal recessive
<i>ASPRV1</i>	No Mendelian disease association in OMIM
<i>ATF2</i>	No Mendelian disease association in OMIM
<i>ATG4D</i>	No Mendelian disease association in OMIM
<i>ATP13A2</i>	Kufor-Rakeb syndrome, Autosomal recessive; Spastic paraplegia 78, autosomal recessive, Autosomal recessive
<i>ATP2A1</i>	Brody myopathy, Autosomal recessive
<i>ATP7A</i>	Menkes disease, X-linked recessive; Occipital horn syndrome, X-linked recessive; Spinal muscular atrophy, distal, X-linked 3, X-linked recessive
<i>BCKDHA</i>	Maple syrup urine disease, type Ia, Autosomal recessive
<i>BEST1</i>	Bestrophinopathy, autosomal recessive; Macular dystrophy, vitelliform, 2, Autosomal dominant; Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma, Autosomal dominant; Retinitis pigmentosa, concentric; Retinitis pigmentosa-50; Vitreoretinopathopathy, Autosomal dominant
<i>BMP15</i>	Ovarian dysgenesis 2; Premature ovarian failure 4
<i>BMP3</i>	No Mendelian disease association in OMIM
<i>BMPRI1B</i>	Acromesomelic dysplasia, Demirhan type, Autosomal recessive; Brachydactyly, type A1, D, Autosomal dominant; Brachydactyly, type A2, Autosomal dominant
<i>BRAF</i>	Cardiofaciocutaneous syndrome, Autosomal dominant; Colorectal cancer, somatic (3); LEOPARD syndrome 3, Autosomal dominant; Melanoma, malignant, somatic (3); Non-small cell lung cancer, somatic (3); Noonan syndrome 7, Autosomal dominant
<i>CAD</i>	Epileptic encephalopathy, early infantile, 50, Autosomal recessive
<i>CAPN1</i>	Spastic paraplegia 76, autosomal recessive, Autosomal recessive
<i>CAT</i>	Acatalasemia

<i>CD320</i> *	Methylmalonic aciduria, transient, due to transcobalamin receptor defect
<i>CDH23</i>	Deafness, autosomal recessive 12, Autosomal recessive;Usher syndrome, type 1D, Autosomal recessive, Digenic recessive;Usher syndrome, type 1D/F digenic, Autosomal recessive, Digenic recessive
<i>CHAT</i>	Myasthenic syndrome, congenital, 6, presynaptic, Autosomal recessive
<i>CHST6</i>	Macular corneal dystrophy, Autosomal recessive
<i>CLCN1</i>	Myotonia congenita, dominant, Autosomal dominant;Myotonia congenita, recessive, Autosomal recessive;Myotonia levior, recessive (3)
<i>CLN6</i>	Ceroid lipofuscinosis, neuronal, 6, Autosomal recessive;Ceroid lipofuscinosis, neuronal, Kufs type, adult onset, Autosomal recessive
<i>CNGA3</i>	Achromatopsia 2, Autosomal recessive
<i>CNGB3</i>	Achromatopsia 3, Autosomal recessive;Macular degeneration, juvenile, Autosomal recessive
<i>CNTNAP1</i>	Lethal congenital contracture syndrome 7, Autosomal recessive
<i>COL10A1</i>	Metaphyseal chondrodysplasia, Schmid type, Autosomal dominant
<i>COL11A2</i>	Deafness, autosomal dominant 13, Autosomal dominant;Deafness, autosomal recessive 53, Autosomal recessive;Fibrochondrogenesis 2, Autosomal recessive, Autosomal dominant;Otospondylomegapiphyseal dysplasia, Autosomal recessive;Stickler syndrome, type III, Autosomal dominant;Weissenbacher-Zweymuller syndrome, Autosomal dominant
<i>COL1A1</i>	Caffey disease, Autosomal dominant;Ehlers-Danlos syndrome, classic, Autosomal dominant;Ehlers-Danlos syndrome, type VIIA, Autosomal dominant;Osteogenesis imperfecta, type I, Autosomal dominant;Osteogenesis imperfecta, type II, Autosomal dominant;Osteogenesis imperfecta, type III, Autosomal dominant;Osteogenesis imperfecta, type IV, Autosomal dominant
<i>COL2A1</i>	Achondrogenesis, type II or hypochondrogenesis, Autosomal dominant;Avascular necrosis of the femoral head, Autosomal dominant;Czech dysplasia, Autosomal dominant;Epiphyseal dysplasia, multiple, with myopia and deafness, Autosomal dominant;Kniest dysplasia, Autosomal dominant;Legg-Calve-Perthes disease, Autosomal dominant;Osteoarthritis with mild chondrodysplasia, Autosomal dominant;Otospondylomegapiphyseal dysplasia, Autosomal recessive;Platyspondylic skeletal dysplasia, Torrance type, Autosomal dominant;SED congenita, Autosomal dominant;SMED Strudwick type, Autosomal dominant;Spondyloepiphyseal dysplasia, Stanescu type, Autosomal dominant;Spondyloperipheral dysplasia, Autosomal dominant;Stickler syndrome, type I, nonsyndromic ocular, Autosomal dominant;Stickler syndrome, type I, Autosomal dominant;Vitreoretinopathy with phalangeal epiphyseal dysplasia (3)

<i>COL5A1</i>	Ehlers-Danlos syndrome, classic type, Autosomal dominant
<i>COL5A2</i>	Ehlers-Danlos syndrome, classic type, Autosomal dominant
<i>COL6A3</i>	Bethlem myopathy 1, Autosomal recessive, Autosomal dominant;Dystonia 27, Autosomal recessive;Ullrich congenital muscular dystrophy 1, Autosomal recessive, Autosomal dominant
<i>COL7A1</i>	EBD inversa, Autosomal recessive;EBD, Bart type, Autosomal dominant;EBD, localisata variant (3);Epidermolysis bullosa dystrophica, AD, Autosomal dominant;Epidermolysis bullosa dystrophica, AR, Autosomal recessive;Epidermolysis bullosa pruriginosa, Autosomal recessive, Autosomal dominant;Epidermolysis bullosa, pretibial, Autosomal recessive, Autosomal dominant;Toenail dystrophy, isolated, Autosomal dominant;Transient bullous of the newborn, Autosomal recessive, Autosomal dominant
<i>COLQ</i>	Myasthenic syndrome, congenital, 5, Autosomal recessive
<i>COPA</i> *	No Mendelian disease association in OMIM
<i>CORIN</i>	Preeclampsia/eclampsia 5
<i>CPT1C</i>	No Mendelian disease association in OMIM
<i>CSNK1G2</i> *	No Mendelian disease association in OMIM
<i>CTSD</i> *	Ceroid lipofuscinosis, neuronal, 10, Autosomal recessive
<i>CYB5R3</i> *	Methemoglobinemia, type I, Autosomal recessive;Methemoglobinemia, type II, Autosomal recessive
<i>CYP26C1</i>	Focal facial dermal dysplasia 4, Autosomal recessive
<i>DKK4</i>	No Mendelian disease association in OMIM
<i>DMD</i>	Becker muscular dystrophy, X-linked recessive;Cardiomyopathy, dilated, 3B, X-linked;Duchenne muscular dystrophy, X-linked recessive
<i>DNM1</i>	Epileptic encephalopathy, early infantile, 31, Autosomal dominant
<i>DNM2</i>	Charcot-Marie-Tooth disease, axonal, type 2M, Autosomal dominant;Charcot-Marie-Tooth disease, dominant intermediate B, Autosomal dominant;Lethal congenital contracture syndrome 5, Autosomal recessive;Myopathy, centronuclear, Autosomal dominant
<i>DPYS</i>	Dihydropyrimidinuria, Autosomal recessive
<i>DSP</i>	Arrhythmogenic right ventricular dysplasia 8, Autosomal dominant;Cardiomyopathy, dilated, with woolly hair and keratoderma,

	Autosomal recessive;Dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis, Autosomal dominant;Epidermolysis bullosa, lethal acantholytic, Autosomal recessive;Keratosis palmoplantaris striata II;Skin fragility-woolly hair syndrome, Autosomal recessive
<i>DUOX2</i>	Thyroid dysmorphogenesis 6, Autosomal recessive
<i>EDN2</i>	No Mendelian disease association in OMIM
<i>EDNRA</i>	Mandibulofacial dysostosis with alopecia, Autosomal dominant
<i>ENAM</i>	Amelogenesis imperfecta, type IB, Autosomal dominant;Amelogenesis imperfecta, type IC, Autosomal recessive
<i>ENTREP2</i>	No Mendelian disease association in OMIM
<i>ETFDH</i>	Glutaric acidemia IIC, Autosomal recessive
<i>F11</i>	Factor XI deficiency, autosomal dominant;Factor XI deficiency, autosomal recessive
<i>F12</i>	Angioedema, hereditary, type III, Autosomal dominant;Factor XII deficiency, Autosomal recessive
<i>F8</i>	Hemophilia A, X-linked recessive
<i>F9</i>	Hemophilia B, X-linked recessive;Thrombophilia, X-linked, due to factor IX defect
<i>FAM20C</i>	Raine syndrome, Autosomal recessive
<i>FAM83G</i>	No Mendelian disease association in OMIM
<i>FBNI</i>	Acromicric dysplasia, Autosomal dominant;Ectopia lentis, familial, Autosomal dominant;Geleophysic dysplasia 2, Autosomal dominant;MASS syndrome;Marfan lipodystrophy syndrome, Autosomal dominant;Marfan syndrome, Autosomal dominant;Stiff skin syndrome, Autosomal dominant;Weill-Marchesani syndrome 2, dominant, Autosomal dominant
<i>FGF5</i>	Trichomegaly, Autosomal recessive
<i>FGFR2</i>	Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis, Autosomal recessive;Apert syndrome, Autosomal dominant;Beare-Stevenson cutis gyrata syndrome, Autosomal dominant;Bent bone dysplasia syndrome, Autosomal dominant;Craniofacial-skeletal-dermatologic dysplasia, Autosomal dominant;Craniosynostosis, nonspecific (3);Crouzon syndrome, Autosomal dominant;Gastric cancer, somatic;Jackson-Weiss syndrome, Autosomal dominant;LADD syndrome, Autosomal dominant;Pfeiffer syndrome, Autosomal dominant;Saethre-Chotzen syndrome, Autosomal dominant;Scaphocephaly and Axenfeld-Rieger anomaly (3);Scaphocephaly, maxillary retrusion, and mental retardation

<i>FGFR3</i>	Achondroplasia, Autosomal dominant;Bladder cancer, somatic;CATSHL syndrome, Autosomal recessive, Autosomal dominant;Cervical cancer, somatic;Colorectal cancer, somatic;Crouzon syndrome with acanthosis nigricans, Autosomal dominant;Hypochondroplasia, Autosomal dominant;LADD syndrome, Autosomal dominant;Muenke syndrome, Autosomal dominant;Nevus, epidermal, somatic;SADDAN, Autosomal dominant;Spermatocytic seminoma, somatic;Thanatophoric dysplasia, type I, Autosomal dominant;Thanatophoric dysplasia, type II, Autosomal dominant
<i>FLCN</i> *	Birt-Hogg-Dube syndrome, Autosomal dominant;Colorectal cancer, somatic;Pneumothorax, primary spontaneous, Autosomal dominant;Renal carcinoma, chromophobe, somatic
<i>FZD7</i>	No Mendelian disease association in OMIM
<i>G6PC1</i>	Glycogen storage disease Ia, Autosomal recessive
<i>GALC</i>	Krabbe disease, Autosomal recessive
<i>GART</i>	No Mendelian disease association in OMIM
<i>GDF9</i>	No associated disease in OMIM
<i>GFAP</i>	Alexander disease, Autosomal dominant
<i>GLB1</i>	GM1-gangliosidosis, type I, Autosomal recessive;GM1-gangliosidosis, type II, Autosomal recessive;GM1-gangliosidosis, type III, Autosomal recessive;Mucopolysaccharidosis type IVB (Morquio), Autosomal recessive
<i>GUSB</i>	Mucopolysaccharidosis VII, Autosomal recessive
<i>HCRTR2</i>	No Mendelian disease association in OMIM
<i>HES7</i>	Spondylocostal dysostosis 4, autosomal recessive, Autosomal recessive
<i>HEXA</i>	GM2-gangliosidosis, several forms, Autosomal recessive;Tay-Sachs disease, Autosomal recessive
<i>HMBS</i>	Porphyria, acute intermittent, Autosomal dominant;Porphyria, acute intermittent, nonerythroid variant, Autosomal dominant
<i>IARS1</i>	No Mendelian disease association in OMIM
<i>IFT122</i>	Cranioectodermal dysplasia 1, Autosomal recessive
<i>ITGA2B</i>	Bleeding disorder, platelet-type, 16, autosomal dominant, Autosomal dominant;Glanzmann thrombasthenia, Autosomal recessive;Thrombocytopenia, neonatal alloimmune, BAK antigen related (3)

<i>ITGA3</i>	Interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital, Autosomal recessive
<i>ITGB2</i>	Leukocyte adhesion deficiency, Autosomal recessive
<i>KCNQ1</i>	No Mendelian disease association in OMIM
<i>KCNJ10</i>	Enlarged vestibular aqueduct, digenic, Autosomal recessive;SESAME syndrome, Autosomal recessive
<i>KDM2B</i>	No Mendelian disease association in OMIM
<i>KDSR</i>	Lymphoma/leukemia, B-cell, variant (1)
<i>KIF1C</i>	Spastic ataxia 2, autosomal recessive, Autosomal recessive
<i>KIF3B</i>	No Mendelian disease association in OMIM
<i>KIT</i>	Gastrointestinal stromal tumor, familial, Autosomal dominant, Isolated cases;Germ cell tumors, Somatic mutation;Leukemia, acute myeloid, Autosomal dominant;Mast cell disease, Autosomal dominant;Piebaldism, Autosomal dominant
<i>KLKB1</i>	Fletcher factor (prekallikrein) deficiency, Autosomal recessive
<i>KRT25</i>	Woolly hair, autosomal recessive 3, Autosomal recessive
<i>KRT27</i>	No Mendelian disease association in OMIM
<i>KRT5</i>	Dowling-Degos disease 1, Autosomal dominant;Epidermolysis bullosa simplex, Dowling-Meara type, Autosomal dominant;Epidermolysis bullosa simplex, Koebner type, Autosomal dominant;Epidermolysis bullosa simplex, Weber-Cockayne type, Autosomal dominant;Epidermolysis bullosa simplex, recessive 1, Autosomal recessive;Epidermolysis bullosa simplex-MP, Autosomal dominant;Epidermylysis bullosa simplex-MCR
<i>KRT71</i>	No Mendelian disease association in OMIM
<i>L2HGDH</i>	L-2-hydroxyglutaric aciduria, Autosomal recessive
<i>LAMA3</i>	Epidermolysis bullosa, generalized atrophic benign, Autosomal recessive;Epidermolysis bullosa, junctional, Herlitz type, Autosomal recessive;Laryngoonychocutaneous syndrome, Autosomal recessive
<i>LAMB3</i>	Amelogenesis imperfecta, type IA, Autosomal dominant;Epidermolysis bullosa, junctional, Herlitz type, Autosomal recessive;Epidermolysis bullosa, junctional, non-Herlitz type, Autosomal recessive
<i>LAMP3</i>	No Mendelian disease association in OMIM

<i>LDLR</i>	Hypercholesterolemia, familial, Autosomal dominant;LDL cholesterol level QTL2, Autosomal dominant
<i>LOXHD1</i>	Deafness, autosomal recessive 77, Autosomal recessive
<i>LRP4</i>	Cenani-Lenz syndactyly syndrome, Autosomal recessive;Sclerosteosis 2, Autosomal recessive, Autosomal dominant
<i>LVRN</i>	No Mendelian disease association in OMIM
<i>LYST</i>	Chediak-Higashi syndrome, Autosomal recessive
<i>MAN2B1</i>	Mannosidosis, alpha-, types I and II, Autosomal recessive
<i>MARS2</i>	Spastic ataxia 3, autosomal recessive, Autosomal recessive
<i>MC1R</i>	Skin/hair/eye pigmentation
<i>MC4R</i>	Obesity, autosomal dominant, Autosomal recessive, Autosomal dominant, Multifactorial
<i>MITF</i>	COMMAD syndrome, Autosomal recessive;Tietz albinism-deafness syndrome, Autosomal dominant;Waardenburg syndrome, type 2A, Autosomal dominant;Waardenburg syndrome/ocular albinism, digenic, Autosomal dominant
<i>MLPH</i>	Griscelli syndrome, type 3, Autosomal recessive
<i>MOCOS</i>	Xanthinuria, type II, Autosomal recessive
<i>MRC2</i>	No Mendelian disease association in OMIM
<i>MSTN</i>	Muscle hypertrophy
<i>MTBP</i>	No Mendelian disease association in OMIM
<i>MTM1</i>	Myotubular myopathy, X-linked, X-linked recessive
<i>MX1</i>	No Mendelian disease association in OMIM
<i>MYBPC1</i>	Congenital myopathy 16
<i>MYBPC3</i>	Cardiomyopathy, dilated, 1MM, Autosomal dominant;Cardiomyopathy, hypertrophic, 4, Autosomal dominant;Left ventricular noncompaction 10, Autosomal dominant
<i>MYH1</i>	No Mendelian disease association in OMIM

<i>MYH7</i>	Cardiomyopathy, dilated, 1S, Autosomal dominant;Cardiomyopathy, hypertrophic, 1, Autosomal dominant;Laing distal myopathy, Autosomal dominant;Left ventricular noncompaction 5, Autosomal dominant;Myopathy, myosin storage, autosomal dominant, Autosomal dominant;Myopathy, myosin storage, autosomal recessive, Autosomal recessive;Scapuloperoneal syndrome, myopathic type, Autosomal dominant
<i>MYO7A</i>	Deafness, autosomal dominant 11, Autosomal dominant;Deafness, autosomal recessive 2, Autosomal recessive;Usher syndrome, type 1B, Autosomal recessive
<i>NAGLU</i>	Mucopolysaccharidosis type IIIB (Sanfilippo B), Autosomal recessive
<i>NAPEPLD</i>	No Mendelian disease association in OMIM
<i>NDRG1</i>	Charcot-Marie-Tooth disease, type 4D, Autosomal recessive
<i>NECAP1</i>	No Mendelian disease association in OMIM
<i>NHLRC2</i>	No Mendelian disease association in OMIM
<i>NPC1</i>	Niemann-Pick disease, type C1, Autosomal recessive;Niemann-Pick disease, type D, Autosomal recessive
<i>NSDHL</i>	CHILD syndrome, X-linked dominant;CK syndrome, X-linked recessive
<i>NUBPL</i>	Mitochondrial complex I deficiency, Autosomal recessive, X-linked dominant, Mitochondrial
<i>P3H2</i>	Myopia, high, with cataract and vitreoretinal degeneration, Autosomal recessive
<i>PAX3</i>	Craniofacial-deafness-hand syndrome, Autosomal dominant;Rhabdomyosarcoma 2, alveolar, Autosomal recessive;Waardenburg syndrome, type 1, Autosomal dominant;Waardenburg syndrome, type 3, Autosomal recessive, Autosomal dominant
<i>PCDH15</i>	Deafness, autosomal recessive 23, Autosomal recessive;Usher syndrome, type 1D/F digenic, Autosomal recessive, Digenic recessive;Usher syndrome, type 1F, Autosomal recessive
<i>PFAS</i>	No Mendelian disease association in OMIM
<i>PFKM</i>	Glycogen storage disease VII, Autosomal recessive
<i>PIGN</i>	Multiple congenital anomalies-hypotonia-seizures syndrome 1, Autosomal recessive
<i>PITX3</i>	Anterior segment dysgenesis 1, multiple subtypes, Autosomal dominant;Cataract 11, multiple types, Autosomal dominant;Cataract 11, syndromic, Autosomal dominant


<i>PKD1</i>	Polycystic kidney disease, adult type I, Autosomal dominant
<i>PKLR</i>	Adenosine triphosphate, elevated, of erythrocytes, Autosomal dominant;Pyruvate kinase deficiency, Autosomal recessive
<i>PLN</i>	Cardiomyopathy, dilated, 1P;Cardiomyopathy, hypertrophic, 18, Autosomal dominant
<i>PLOD1</i> *	Ehlers-Danlos syndrome, type VI, Autosomal recessive
<i>PLP1</i>	Pelizaeus-Merzbacher disease, X-linked recessive;Spastic paraplegia 2, X-linked, X-linked recessive
<i>PLP2</i>	No Mendelian disease association in OMIM
<i>PMEL</i>	No Mendelian disease association in OMIM
<i>PNKP</i>	Ataxia-oculomotor apraxia 4, Autosomal recessive;Microcephaly, seizures, and developmental delay, Autosomal recessive
<i>PNPLA8</i>	No Mendelian disease association in OMIM
<i>PPARD</i>	No Mendelian disease association in OMIM
<i>PPIB</i> *	Osteogenesis imperfecta, type IX, Autosomal recessive
<i>PRCD</i>	Retinitis pigmentosa 36
<i>PRKAG3</i>	[No associated Mendelian disease in OMIM] Skeletal muscle glycogen content and metabolism trait locus
<i>PRL</i>	No Mendelian disease association in OMIM
<i>PRNP</i>	Cerebral amyloid angiopathy, PRNP-related, Autosomal dominant;Creutzfeldt-Jakob disease, Autosomal dominant;Gerstmann-Straussler disease, Autosomal dominant;Huntington disease-like 1, Autosomal dominant;Insomnia, fatal familial, Autosomal dominant;Prion disease with protracted course, Autosomal dominant
<i>PSMB7</i> *	No Mendelian disease association in OMIM
<i>PYGM</i>	McArdle disease, Autosomal recessive
<i>RAB24</i>	No Mendelian disease association in OMIM
<i>RABGGTB</i> *	No Mendelian disease association in OMIM
<i>RASGRP2</i>	No Mendelian disease association in OMIM

<i>RDH5</i>	Fundus albipunctatus, Autosomal recessive, Autosomal dominant
<i>RETREG1</i>	Neuropathy, hereditary sensory and autonomic, type IIB, Autosomal recessive
<i>RHO</i>	Night blindness, congenital stationary, autosomal dominant 1;Retinitis pigmentosa 4, autosomal dominant or recessive, Autosomal recessive, Autosomal dominant;Retinitis punctata albescens, Autosomal recessive, Autosomal dominant
<i>RYR1</i>	Central core disease, Autosomal recessive, Autosomal dominant;King-Denborough syndrome, Autosomal dominant;Minicore myopathy with external ophthalmoplegia, Autosomal recessive;Neuromuscular disease, congenital, with uniform type 1 fiber, Autosomal recessive, Autosomal dominant
<i>SCN8A</i>	Epileptic encephalopathy, early infantile, 13, Autosomal dominant;Seizures, benign familial infantile, 5, Autosomal dominant
<i>SEL1L</i> *	No Mendelian disease association in OMIM
<i>SERPINH1</i>	Osteogenesis imperfecta, type X, Autosomal recessive
<i>SGSH</i>	Mucopolysaccharidosis type IIIA (Sanfilippo A), Autosomal recessive
<i>SLC12A1</i>	Bartter syndrome, type 1, Autosomal recessive
<i>SLC24A5</i>	Albinism, oculocutaneous, type VI, Autosomal recessive
<i>SLC25A12</i>	Epileptic encephalopathy, early infantile, 39, Autosomal recessive
<i>SLC25A46</i>	Neuropathy, hereditary motor and sensory, type VIB, Autosomal recessive
<i>SLC2A9</i>	Hypouricemia, renal, 2, Autosomal recessive, Autosomal dominant
<i>SLC35A3</i>	No Mendelian disease association in OMIM
<i>SLC36A1</i>	No Mendelian disease association in OMIM
<i>SLC39A4</i>	Acrodermatitis enteropathica, Autosomal recessive
<i>SLC3A1</i>	Cystinuria, Autosomal recessive, Autosomal dominant
<i>SLC45A2</i>	Albinism, oculocutaneous, type IV
<i>SLC5A3</i>	No Mendelian disease association in OMIM


<i>SLC6A5</i>	Hyperekplexia 3, Autosomal recessive, Autosomal dominant
<i>SLC7A9</i>	Cystinuria, Autosomal recessive, Autosomal dominant
<i>SMC2</i>	No Mendelian disease association in OMIM
<i>SOD1</i> *	Amyotrophic lateral sclerosis 1, Autosomal recessive, Autosomal dominant
<i>SOWAHB</i>	No Mendelian disease association in OMIM
<i>SPAST</i>	Spastic paraplegia 4, autosomal dominant, Autosomal dominant
<i>STAT5B</i> *	Growth hormone insensitivity with immunodeficiency;Leukemia, acute promyelocytic, somatic
<i>SUGT1</i> *	No Mendelian disease association in OMIM
<i>SUV39H2</i>	No Mendelian disease association in OMIM
<i>TBXT</i>	No Mendelian disease association in OMIM
<i>TECPR2</i>	Spastic paraplegia 49, autosomal recessive, Autosomal recessive
<i>TNXB</i>	Ehlers-Danlos syndrome due to tenascin X deficiency, Autosomal recessive;Vesicoureteral reflux 8, Autosomal dominant
<i>TPO</i>	Thyroid dysmorphogenesis 2A, Autosomal recessive
<i>TRPV4</i>	Brachyolmia type 3, Autosomal dominant;Digital arthropathy-brachydactyly, familial, Autosomal dominant;Hereditary motor and sensory neuropathy, type IIc, Autosomal dominant;Metatropic dysplasia, Autosomal dominant;Parastremmatic dwarfism, Autosomal dominant;SED, Maroteaux type, Autosomal dominant;Scapuloperoneal spinal muscular atrophy, Autosomal dominant;Spinal muscular atrophy, distal, congenital nonprogressive, Autosomal dominant;Spondylometaphyseal dysplasia, Kozlowski type, Autosomal dominant
<i>TSEN54</i>	Pontocerebellar hypoplasia type 2A, Autosomal recessive;Pontocerebellar hypoplasia type 4, Autosomal recessive
<i>TUBB1</i>	Macrothrombocytopenia, autosomal dominant, TUBB1-related, Autosomal dominant
<i>TUBD1</i>	No Mendelian disease association in OMIM
<i>TUBGCP5</i>	No Mendelian disease association in OMIM

<i>TYR</i>	Albinism, oculocutaneous, type IA, Autosomal recessive;Albinism, oculocutaneous, type IB;Waardenburg syndrome/albinism, digenic, Autosomal dominant
<i>TYRP1</i>	Albinism, oculocutaneous, type III, Autosomal recessive
<i>UCHL1</i>	Spastic paraplegia 79, autosomal recessive, Autosomal recessive
<i>UNC93B1</i>	No Mendelian disease association in OMIM
<i>UROD</i> *	Porphyria cutanea tarda, Autosomal dominant;Porphyria, hepatoerythropoietic, Autosomal dominant
<i>UROS</i>	Porphyria, congenital erythropoietic, Autosomal recessive
<i>VPS11</i>	Leukodystrophy, hypomyelinating, 12, Autosomal recessive
<i>VWF</i>	von Willebrand disease, type 1, Autosomal dominant;von Willebrand disease, types 2A, 2B, 2M, and 2N, Autosomal recessive, Autosomal dominant;von Willibrand disease, type 3, Autosomal recessive
<i>WIF1</i>	No Mendelian disease association in OMIM
<i>WWP1</i>	No Mendelian disease association in OMIM
<i>YARS2</i>	Myopathy, lactic acidosis, and sideroblastic anemia 2, Autosomal recessive

Supplemental Figure 1. Human karyogram indicating Mendelian diseases and the associated genes, where orthologous variants were observed in both non-human animals (OMIA) and humans (ClinVar). See text for details. Positions are approximate. Created with [BioRender.com](#).




Supplemental Figure 2. An example of orthologous germline missense variants in *DNM2* (NM_001005361.3:c.1393C>T) affecting the conserved wild-type arginine residue [p.(Arg465Trp)] and causing centronuclear myopathy in both dogs and humans.^{6 7} Created with [BioRender.com](https://www.biorender.com).




Supplemental Figure 3. Odds of the missense variants in non-human animal species extracted from OMIA for which orthologous human variants appear in ClinVar to have been classified in the latter as pathogenic/likely pathogenic (P/LP), compared to benign/likely benign/variant of uncertain significance/conflicting interpretations of pathogenicity (B/LB/VUS/CIP). Created with [BioRender.com](#).


Animal variants in OMIA that overlap with human orthologous variants in ClinVar



Supplemental Figure 4. Bar chart summarizing the evidence type(s) used in publications describing the initial association between a specific missense variant and a phenotype in a non-human animal species, for all variants in OMIA for which orthologous human variants were classified in ClinVar (n=56). Figure created with GraphPad Software.



Supplemental Figure 5. Boxplots of AlphaMissense⁴ pathogenicity scores for the OMIA missense variants absent from ClinVar, comparing with other missense variation in ClinVar in the same gene set. B/LB, Benign/Likely benign; P/LP, Pathogenic/Likely pathogenic; VUS/CIP, variant of uncertain significance/conflicting interpretations of pathogenicity.



Supplemental References

1. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O'Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferreira S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME, Neale BM, Daly MJ, MacArthur DG. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 2020;581(7809):434-43.
2. Sullivan PF, Meadows JRS, Gazal S, Phan BN, Li X, Genereux DP, Dong MX, Bianchi M, Andrews G, Sakthikumar S, Nordin J, Roy A, Christmas MJ, Marinescu VD, Wang C, Wallerman O, Xue J, Yao S, Sun Q, Szatkiewicz J, Wen J, Huckins LM, Lawler A, Keough KC, Zheng Z, Zeng J, Wray NR, Li Y, Johnson J, Chen J, Zoonomia Consortium section s, Paten B, Reilly SK, Hughes GM, Weng Z, Pollard KS, Pfenning AR, Forsberg-Nilsson K, Karlsson EK, Lindblad-Toh K. Leveraging base-pair mammalian constraint to understand genetic variation and human disease. *Science* 2023;380(6643):eabn2937.
3. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, Holzinger E, Karyadi D, Cannon-Albright LA, Teerlink CC, Stanford JL, Isaacs WB, Xu J, Cooney KA, Lange EM, Schleutker J, Carpten JD, Powell IJ, Cussenot O, Cancel-Tassin G, Giles GG, MacInnis RJ, Maier C, Hsieh CL, Wiklund F, Catalona WJ, Foulkes WD, Mandal D, Eeles RA, Kote-Jarai Z, Bustamante CD, Schaid DJ, Hastie T, Ostrander EA, Bailey-Wilson JE, Radivojac P, Thibodeau SN, Whittemore AS, Sieh W. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum Genet* 2016;99(4):877-85.
4. Cheng J, Novati G, Pan J, Bycroft C, Zemgulyte A, Applebaum T, Pritzel A, Wong LH, Zielinski M, Sargeant T, Schneider RG, Senior AW, Jumper J, Hassabis D, Kohli P, Avsec Z. Accurate proteome-wide missense variant effect prediction with AlphaMissense. *Science* 2023;381(6664):eadg7492.
5. Hounkpe BW, Chenou F, de Lima F, De Paula EV. HRT Atlas v1.0 database: redefining human and mouse housekeeping genes and candidate reference transcripts by mining massive RNA-seq datasets. *Nucleic Acids Res* 2021;49(D1):D947-D55.
6. Bohm J, Barthelemy I, Landwerlin C, Blanchard-Gutton N, Relaix F, Blot S, Laporte J, Tired L. A dog model for centronuclear myopathy carrying the most common DNM2 mutation. *Dis Model Mech* 2022;15(4)
7. Bitoun M, Maugenre S, Jeannet PY, Lacene E, Ferrer X, Laforet P, Martin JJ, Laporte J, Lochmuller H, Beggs AH, Fardeau M, Eymard B, Romero NB, Guicheney P. Mutations in dynamin 2 cause dominant centronuclear myopathy. *Nat Genet* 2005;37(11):1207-9.